SlidesetOncologyOxazolidinones for TB: Current Status and Future Prospects - Lawrence GeiterView Slideset
SlidesetOncologyEvaluating Hepatotoxicity of Bedaquiline Treatment in Multi-Drug Resistant Tuberculosis Patients - Lénaïg TanneauView Slideset
SlidesetOncologyRelationship Between Plasma and Intracellular Concentrations of Bedaquiline and its M2 Metabolite in South African Patients with Drug-Resistant TB - Precious NgwaleroView Slideset
SlidesetOncologyPharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB - Ahmed Aliyu AbulfathiView Slideset
SlidesetOncologyCo-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial - Elisa IgnatiusView Slideset
SlidesetOncologyExposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial - Chishala ChabalaView Slideset
SlidesetOncologyEthionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis - Charles PeloquinView Slideset
SlidesetOncologyCan Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis - Frank KloproggeView Slideset
SlidesetOncologyPharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO - Ernesto JaramilloView Slideset
SlidesetOncologyPK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312 - Kamunkhwala GausiView Slideset
SlidesetOncologyPopulation Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis - Charles PeloquinView Slideset
SlidesetOncologyDrug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients - Alan FarajView Slideset
SlidesetOncologyLevofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM - Mathieu BolhuisView Slideset
